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Abstract
The non-genomic mechanisms by which glucocorticoids modulate β2 agonist-inducedbronchodilation remain elusive. Our studies aimed to elucidate mechanisms mediating
the beneficial effects of glucocorticoids on agonist-induced bronchodilation. Utilizing
human precision cut lung slices (hPCLS), we measured bronchodilation to formoterol,
prostaglandin E2 (PGE2), cholera toxin (CTX) or forskolin in the presence and absence of
budesonide. Using cultured human airway smooth muscle (HASM), intracellular cAMP
was measured in live cells following exposure to formoterol, PGE2, or forskolin in the
presence or absence of budesonide.

We showed that simultaneous budesonide

administration amplified formoterol-induced bronchodilation and attenuated agonistinduced phosphorylation of myosin light chain, a necessary signaling event mediating
force generation. In parallel studies, cAMP levels were augmented by simultaneous
exposure of HASM cells to formoterol and budesonide. Budesonide, fluticasone and
prednisone alone rapidly increased cAMP levels, but steroids alone had little effect on
bronchodilation in hPCLS. Bronchodilation induced by PGE2, CTX or forskolin was also
augmented by simultaneous exposure to budesonide in hPCLS. Furthermore, HASM
cells expressed membrane-bound glucocorticoid receptors that failed to translocate with
glucocorticoid stimulation, and that potentially mediated the rapid effects of steroids on β2
agonist-induced bronchodilation. Knockdown of glucocorticoid receptor α had little effect
on budesonide-induced and steroid-dependent augmentation of formoterol-induced
cAMP generation in HASM. Collectively, these studies suggest that glucocorticoids
amplify cAMP-dependent bronchodilation by directly increasing cAMP levels. These
studies identify a molecular mechanism by which the combination of glucocorticoids and
β2 agonists may augment bronchodilation in diseases such as asthma or chronic
obstructive pulmonary disease.

Introduction
Combination therapy including an inhaled glucocorticoid and a long-acting β2
agonist represents a cornerstone in the management of airways disease including asthma
and chronic obstructive pulmonary disease. Conceptually, combined use of an antiinflammatory agent with a bronchodilator improves medication adherence as compared
to using each drug separately (1-3). Use of an inhaled corticosteroid (ICS) with a longacting β2 agonist (LABA) as rescue and maintenance therapy appears more effective than
using an ICS or SABA alone or using an ICS/LABA for maintenance (4-10). Evidence
now suggests, apart from enhanced adherence, combination therapy augments efficacy
of either drug alone (11). We posit that this effect is mediated by a rapid, non-genomic
effect of glucocorticoids. To date, the molecular mechanisms by which non-genomic
effects of glucocorticoids modulate bronchodilation remain unknown. (11).
Glucocorticoids primarily mediate their effects by activating the glucocorticoid
receptor (GR). In this canonical signaling, the GR resides in the cytoplasm in its inactive
state and, upon ligand activation, translocates to the cell nucleus to interact with
glucocorticoid response elements (GREs) and produce genomic effects altering protein
expression. Recent evidence has emerged to suggest that glucocorticoids manifest rapid
non-genomic actions on several signaling processes (11). These non-canonical, nongenomic effects of glucocorticoids appear to involve non-specific interactions with the cell
membrane and/or specific interactions with cytosolic GRs (cGR) or membrane-bound
GRs (mGR). The rapid non-genomic effects appear to, at least in part, be mediated
through a putative mGR (11).
Several studies have reported an interaction of mGR with other membrane
receptors, particularly G protein-coupled receptors (GPCR) (12). Involvement of mGR
and GPCR-dependent mechanisms in the rapid effect (~ 1 min) of corticosterone on
NMDA-evoked currents in hippocampal neurons was demonstrated (12), suggesting that
mGR may couple to multiple G proteins, including Gαs and Gαq/11. Other studies suggest
that mGR directly activates downstream intracellular signaling pathways. Corticosterone
acted via mGR to rapidly elicit PKC-dependent activation of ERK1/2 MAPK pathway in
PC12 cells (13). Interestingly, proteomic analysis of CCRF-CEM cells identified 128
proteins that were differentially regulated by activation of mGR using BSA-conjugated

cortisol briefly (5 and 15 min) (14). These actions were unique to mGR, as no activation
of cGR target genes (e.g. GILZ) were observed. Signal pathway analysis now provides
evidence that mGR is involved in numerous pathways that are also regulated by
glucocorticoids through cGR, suggesting that mGRs trigger early priming events,
ultimately facilitating slower genomic activation by glucocorticoids (14).
Our study identifies a molecular mechanism by which glucocorticoids acutely
amplify β2 agonist-induced bronchodilation. By rapidly stimulating cAMP production,
glucocorticoids augment the primary second messenger signal of β2 agonists and other
bronchodilators. Ultimately, identification of plasma membrane components through
which glucocorticoids impact cAMP signaling and bronchodilation may provide novel
therapeutic targets for airways diseases, an area that has seen little innovation in the past
45 years.

Methods

Reagents
Reagents were purchased from the following vendors: formoterol, forskolin,
carbachol, and TNFα (Sigma Aldrich, St. Louis, MO); budesonide (AstraZeneca); cell
culture media and components (ThermoFisher, Waltham, MA); fetal bovine serum
(Atlanta Biologicals, Flowery Branch, GA); GR antibody (Santa Cruz, Dallas, TX); β-actin
antibody (Sigma Aldrich, St. Louis, MO); phosphorylated GRα (Cell Signaling
Technology, Danvers, MA); rabbit and mouse secondary antibodies for immunoblotting
(LiCor, Lincoln, NE); GRα targeted siRNA (Ambion, Austin, TX); non-targeting siRNA
(Dharmacon, Lafayette, CO); HiPerFect transfection reagent (Qiagen, Germantown, MD);
single analyte ELISA kits for IL-6, RANTES, and IL-8 (R&D Systems, Minneapolis, MN).

hPCLS generation and bronchodilation assays
Human precision cut lung slices (hPCLS) were prepared as previously described
(15). Briefly, whole human lungs from non-asthma donors were dissected and inflated
using 2% (wt/vol) low melting point agarose. Once the agarose set, the lobe was
sectioned, and cores of 8-mm diameter were made. Cores containing small airways by

visual inspection were sliced at a thickness of 350 μm (Precisionary Instruments VF300
Vibratome, Greenville, NC) and collected in wells containing supplemented Ham’s F-12
medium. To study bronchodilation, small airways contained within hPCLS were
contracted with carbachol (CCh, 10-5 M), and then bronchodilated to formoterol (10-12 –
10-6 M), budesonide (10-12 – 10-5 M), forskolin (10-12 – 10-5 M), PGE2 (10-10 – 10-5 M), or
cholera toxin (0.01-100 µg/ml) ± budesonide (10-5 M, simultaneous administration).
Human lung tissue samples were commercially obtained from anonymous donors
(National Disease Research Interchange, Philadelphia, PA or the International Institute
for the Advancement of Medicine, Edison, NJ), and are therefore exempt from IRB
(Institutional Review Board) approval. Although these samples have demographic
information, there is no information linking the subject’s identification to the tissue.
Integrated area under the curve (AUC - % dilation/bronchodilator dose) was calculated
from the dose response curves and was plotted along with maximal bronchodilation
achieved over the entire dose response curve.

Human airway smooth muscle (HASM) cells
HASM cells were derived from tracheas obtained from non-asthma donor lungs
that hPCLS were derived from. HASM cell culture was performed as described previously
(16). Briefly, the cells were cultured in Ham’s F-12 medium supplemented with 10% FBS,
100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2.5 mg/ml amphotericin B, and this
medium was replaced every 72 hr. HASM cells in subculture during passages 1–5 were
used, because these cells retain expression of native contractile proteins, as
demonstrated by immunocytochemical staining for smooth muscle actin and myosin (17).

cAMP assays
For kinetic measurement of cAMP production in live cells, subconfluent HASM
cells were plated in black-walled, clear flat bottom 96-well plates with HASM media,
BacMam virus expressing the green cAMP difference detector in situ (cADDis) cAMP
sensor (Montana Molecular, Bozeman, MT), and 1 μM trichostatin-A (Sigma Aldrich, St.
Louis, MO) per well and grown overnight. Media was aspirated and replaced with PBS
without calcium or magnesium, then the plate was covered and incubated at room

temperature. Cell fluorescence was read from the plate bottom using excitation/emission
wavelengths of 494 nm and 522 nm, respectively, using a SpectraMax M5 plate reader
(Molecular Devices, Sunnyvale, CA). A kinetic read (5 min) on unstimulated cells was
performed to determine variability in each well’s fluorescence (≤5%). Cells were
stimulated with agonist and fluorescence changes were read at 30 second intervals for
30 min.

Cell surface biotinylation
Cell surface protein biotinylation was carried out according to manufacturer’s
protocols (Pierce Biotechnology, Rockford, IL). Cells were grown to 90-95% confluence,
incubated with a biotin solution, then scraped and lysed. Lysates were incubated with
NeutrAvidin beads, then bound proteins eluted off. Eluates were assessed for
glucocorticoid receptor, using epidermal growth factor receptor (EGFR; Cell Signaling
Technology, Danvers, MA) as a positive control for cell surface biotinylation. Remaining
cell lysates were examined for expression of GAPDH (Millipore, Burlington, MA) and
COXIV (Cell Signaling Technology, Danvers, MA) as measures of intracellular/cytosolic
proteins.

Immunohistochemistry
HASM cells were grown in chamber slides until confluent, then serum starved for
18 hr. Cells were then fixed with 1% paraformaldehyde, washed, then blocked with 1%
BSA/PBS solution containing 10% FcR block (Miltenyi Biotec, Auburn, CA). Cells were
stained with a GR antibody (rabbit, Santa Cruz Biotechnology, Dallas, TX) in 1%
BSA/PBS solution overnight. The slides were washed, stained with biotin-coated donkey
anti-rabbit antibody (Jackson Immunolabs, Bar Harbor, ME) in 1% BSA/PBS, washed,
then incubated with a streptavidin-Alexa Fluor 488 conjugated antibody (Jackson
Immunolabs). The slides were washed, then the cells were permeabilized with 0.01%
Triton X-100 and stained with DAPI. Slides were cover-slipped and imaged.

Immunoblotting

HASM cells were treated with carbachol (25 µM Cch, 10 min) then with formoterol
(100 pM, 5 min) ± simultaneous budesonide stimulation (1 µM, 5 min). Cells were then
treated with 500 M perchloric acid, plates scraped, and cells pelleted. Pellets were
solubilized in RIPA and sonicated prior to being subjected to SDS PAGE and transferred
to nitrocellulose membranes, as previously described (18) then assessed for
phosphorylation of MLC and total MLC. Total GRα and phospho-GRα were assessed in
cell lysates following siRNA transfection of HASM with non-targeting and GRα-targeted
siRNA.

Single analyte ELISAs
HASM transfected with non-targeting or GRα-targeted siRNA were treated with
budesonide (100 nM, 1 hr) prior to stimulation with TNFα (10 ng/ml, 24 hr). Single analyte
ELISAs were utilized to assess release of IL-6, RANTES, and IL-8 into the media. Each
condition represents duplicate samples from a single donor, each run in triplicate.

Statistical analyses
Standard curves for cAMP generation were fitted and unknown values
extrapolated using GraphPad Prism 6.0h (GraphPad Software Inc., San Diego, CA). Data
are presented as the mean ± SEM. Statistical comparisons (t-tests and one-way analysis
of variance) were performed and graphics were generated using GraphPad Prism 6.0h
(GraphPad Software Inc.). Unpaired non-parametric analyses were used for hPCLS data
that was not normally distributed to compare conditions. Paired parametric analysis was
used for HASM experiments (ELISA, western blots, and cAMP generation).

Results

Budesonide enhances formoterol-induced bronchodilation
To examine whether a glucocorticoid and a β2 agonist can additively promote
bronchodilation, human small airways in hPCLS were preconstricted to carbachol and
then dilated to formoterol in the absence and presence of budesonide, with the
budesonide being added simultaneously with the formoterol. Budesonide treatment

augmented formoterol-induced bronchodilation (Figure 1), increasing maximal levels of
bronchodilation. Similarly, the integrated bronchodilator response as represented by Area
Under the Curve (AUC) significantly increased. Budesonide alone had little effect on
luminal diameter dilation despite being administered at similar concentrations as
formoterol (data not shown). These data show that simultaneous administration of
budesonide augments β2 agonist-induced dilation of human small airways.

Budesonide amplifies PGE2-, cholera toxin- and forskolin-mediated bronchodilation
Given that budesonide augments airway dilation to a β2 agonist, we next examined
whether budesonide enhances dilation mediated by activation of other GPCRs coupled
to Gαs or via direct activation of Gαs or adenylyl cyclase. We showed that simultaneous
administration of budesonide enhances PGE2-induced bronchodilation of airways (Figure
2), with increases in maximal bronchodilation and AUC to PGE2. To assess whether the
effect of budesonide was due to activation of Gαs, a G protein shared between the β2AR
and EP2/4 receptors, we utilized cholera toxin (CTX) to induce bronchodilation in hPCLS.
Simultaneous administration of budesonide with CTX induced greater maximal
bronchodilation overall responses to CTX compared to CTX alone (Figure 3). To assess
whether budesonide enhanced direct adenylyl cyclase (AC)-induced bronchodilation,
hPCLS were exposed to forskolin (FSK) in the presence or absence of budesonide.
Simultaneous budesonide administration enhanced FSK-induced bronchodilation (Figure
4), significantly increasing the AUC to FSK compared to control.

Budesonide enhances formoterol-stimulated cAMP production
To

dissect

the

molecular

pathways

by

which

budesonide

augments

bronchodilation of human airway smooth muscle (HASM), HASM were infected with a
recombinant BacMam expressing a fluorescent cAMP sensor, cADDis, and cAMP levels
were measured after exposure to varying concentrations of formoterol. The cADDis
sensor decreases fluorescence upon binding cAMP, providing real-time assessment of
intracellular cAMP levels without inclusion of phosphodiesterase (PDE) inhibitors.
Formoterol decreased cADDis fluorescence within minutes that typically stabilized within
15-20 min (Figure 5A, inset). To account for the rate and maximal levels of cAMP

production produced by formoterol, the product of the decay rate (K) and the level at
steady state (plateau) were plotted for each drug concentration. Using this analysis,
formoterol increased cAMP levels (Figure 5A). In parallel, formoterol-stimulated cAMP
was measured in HASM treated with vehicle or 10-6 M budesonide given simultaneously.
Budesonide shifted the formoterol concentration-response curve 3.9-fold leftward (Figure
5B. Additionally, budesonide at 1 or 10 µM augmented formoterol-induced cAMP
production, but that effect was not realized at 100 nM budesonide. The effect of
budesonide on formoterol-stimulated cAMP production in HASM cells therefore mimicked
the effect of budesonide on agonist-induced bronchodilation observed in hPCLS.

Budesonide enhances PGE2- and forskolin-stimulated cAMP production
To determine whether budesonide also enhanced cAMP signaling stimulated by
PGE2, PGE2-stimulated cAMP production was detected by cADDis in a concentrationdependent manner (Figure 5C). Inclusion of budesonide (1 µM) shifted the PGE 2 curve
leftward 8.4-fold. We next examined cAMP responses to forskolin (FSK), finding that FSKstimulated cAMP production was shifted leftward 8.2-fold by inclusion of 1 µM budesonide
as compared to vehicle (Figure 5D). These data are consistent with the notion that
budesonide enhances cAMP production initiated by multiple GPCRs in different signaling
compartments in HASM cells, and that budesonide-mediated augmentation of these
responses is receptor-independent.

Budesonide, fluticasone and prednisone enhance directly stimulated cAMP production
Because budesonide enhanced agonist-induced cAMP signaling, we investigated
whether budesonide alone stimulated cAMP. Significant decreases in cADDis
fluorescence was observed within seconds of addition of 1 or 10 µM budesonide (data
not shown). 10 µM budesonide stimulated cAMP levels that were statistically different
than vehicle within 2 minutes, while 1 µM induced significant changes within 5 minutes.
The higher concentration of budesonide stimulated changes in cADDis fluorescence that
were equivalent to maximal concentrations of forskolin (10 µM) or formoterol (not shown).
However, cADDis is a readily saturated sensor so high levels of cAMP may not be
distinguishable (19). We also examined cAMP production by other corticosteroids, finding

that fluticasone and prednisone (data not shown) stimulated cAMP production.
Fluticasone was equi-effective as budesonide although greater inter-experimental
variability was observed while prednisone was less efficacious and less potent.

A membrane-bound form of GR (mGR) is present in HASM cells
Since budesonide effects on cAMP generation and bronchodilation were rapid, we
posited that budesonide activates a membrane-associated receptor. Other laboratories
have identified a mGR that can evoke immediate steroid effects in other cell types (2022). Using cell-surface biotin labeling and immunohistochemistry (Figure 6), we showed
that HASM express mGRs that fail to translocate to the nucleus from the membrane
despite stimulation with a glucocorticoid (dexamethasone). As expected, cytosolic GR
translocated to the nucleus as shown in Figure 6.

Budesonide augments formoterol-induced dephosphorylation of myosin light chain
Contractile agonists activate GPCRs that evoke HASM shortening by promoting
phosphorylation of myosin light chain (pMLC). To determine whether formoterol in the
absence and presence of budesonide modulates agonist-induced excitation-contraction
signaling, we examined attenuation of carbachol-induced pMLC by formoterol ±
budesonide. Formoterol alone (10 pM – 10 nM) induced significant reversal of carbacholinduced pMLC, and simultaneous administration of budesonide with formoterol (at 100
pM) further augments formoterol-induced pMLC dephosphorylation (Figure 7). These
data suggest that glucocorticoids can also augment formoterol effects on pro-contractile
pathways in HASM cells.
GRα knockdown in HASM cells has little effect on cAMP generation in response to
budesonide or budesonide + formoterol
To more directly assess the role of the GR in mediating rapid cAMP responses
to glucocorticoids,

we

used

siRNA

to

knock

down

GRα expression

in

HASM. Transfection of validated siRNA sequences into HASM led to a nearly complete
loss of GRα immunoreactivity (detected as a doublet of approximately 94 kDa) as
compared

to

cells

transfected

with

a scrambled

siRNA

(Figure

8A). GRα mRNA expression in control HASM was readily detected by quantitative RTPCR but was undetectable in cells transfected with GRα siRNA (not shown). We
then assessed cAMP levels in HASM following siRNA transfection. Forskolin-stimulated
cAMP responses were unaltered by GRα knockdown, implying that loss of GRα did not
alter AC expression or function (data not shown). Budesonide (1 µM) or formoterol (0.1
nM) each elicited equivalent cAMP responses in both GRα knockdown and control cells
(Figure 8B and 8C). cAMP responses to simultaneous addition of budesonide and
formoterol were greater than either agent alone, but were similar in both control
and GR⍺ knockdown conditions (Figure 8D). Knockdown of GRα was confirmed by
immunoblot, and showed reversal of budesonide attenuation of TNFα-induced
inflammatory mediator release (data not shown).

These results suggest that

GRα expression may not be required for rapid, non-genomic signaling by GC.

Discussion
In airway smooth muscle, contractile agonists stimulate Ca2+-dependent signaling
evoking cell shortening regulated in part through increased [Ca2+]i transients, inhibition of
sarcoplasmic reticulum Ca2+-ATPase (SERCA), and pMLC inducing actin-myosin crossbridge cycling and force generation. Agents that mobilize cAMP and activate protein
kinase A (PKA) protect against or reverse agonist-induced bronchoconstriction. In
epithelial cells and neurons, glucocorticoids modulate signaling pathways that promote
relaxation of HASM. Dexamethasone stimulation of bronchial cells attenuated [Ca2+]i
currents, which was reversed by SERCA inhibitors, PKA, and activated adenylyl cyclase
(AC) within minutes (20). Further, corticosterone treatment reversed ATP-induced [Ca2+]i
transients in mouse HT4 neuroblastoma cells (23). In primary HASM cells, budesonide
stimulation alone increased cAMP levels (data not shown). Interestingly, we show that
simultaneous budesonide and formoterol significantly reduced carbachol-induced pMLC
(Figure 7), but little effect of budesonide alone. Others noted existence of a mGR that
may mediate non-genomic, rapid effects of glucocorticoids. We demonstrate presence of
mGR in HASM (Figure 6) that does not translocate upon glucocorticoid stimulation. Our

work suggests that expression of GRα is not necessary to elicit cAMP production in
response to budesonide or budesonide + formoterol (Figure 8). There is a possibility that
residual GR protein whose expression was not attenuated by siRNA transfection may
mediate the effect, but the existence of a modified GR that may not be subject to
knockdown of the protein may mediate the effects of steroids on cAMP
production/augmentation of bronchodilation. Overall, these data suggest that despite the
effect of glucocorticoids on attenuation of Ca2+-dependent pathways, glucocorticoids
alone had little effect on agonist-induced bronchoconstriction of small airways (data not
shown) in hPCLS but rather, amplified β2 agonist-induced bronchodilation.
Although glucocorticoids alone induced cAMP production (data not shown), these
steroids had little effect on bronchodilation of small airways in hPCLS (data not shown).
Robust and sensitive assessment of cAMP pools is achieved using the cADDis reporter
(19). Although the assay shows increases in cAMP production to budesonide alone, this
increase in cAMP levels may be insufficient for promoting bronchodilation due to an
inadequate magnitude or localization of the cAMP signal despite utilizing the same
concentrations of budesonide as formoterol in the hPCLS bronchodilation assays (10-12
– 10-5 M, data not shown). Glucocorticoids may therefore be increasing cAMP levels via
direct activation of Gαs, activation of an unidentified GPCR, or inhibition of
phosphodiesterases. Others suggest that increases in intracellular cAMP elicited by
glucocorticoids may be due to inhibition of ABCC4, an ATP binding cassette transporter
that pumps cAMP into the extracellular space. In differentiated airway epithelial cells,
dexamethasone, but not budesonide, augmented activity of GRE-luciferase when given
with forskolin treatment. Additionally, blockade of ABCC4 potentiated activity of the GREluciferase in the presence of either dexamethasone or budesonide treatment (24). Unlike
airway epithelial cells, β2 agonist or forskolin treatment had little effect on extracellular
levels of cAMP in HASM (data not shown).

However, we reported that ABCC4 is

expressed in HASM cells, and its expression is augmented by budesonide treatment (25).
In the aforementioned studies, glucocorticoid treatment was for 6-12 hours, conceivably
the mechanisms modulating rapid glucocorticoid stimulation may differ. Future studies
will address whether non-genomic effects of glucocorticoids are mediated by activation
of ABCC4 proteins.

Others noted acute glucocorticoid stimulation activates signaling pathway
components in non-muscle cells that are associated with bronchodilatory responses in
smooth muscle. In bronchial epithelial cells dexamethasone inhibited agonist-induced
[Ca2+]i, with the inhibition sensitive to AC and PKA inhibition (20). Other show a nongenomic glucocorticoid effect that was PKA-dependent in a neural cell line (23).
Accordingly, to assess mechanisms by which steroid may be augmenting agonist-induced
bronchodilation we examined the effect of glucocorticoids on: (1) selectivity of responses
we observed to the β2AR; (2) direct activation of Gαs; and (3) whether the response
observed was receptor-dependent. We found that PGE2-, CTX-, and FSK-stimulated
bronchodilation of small airways (Figures 2, 3 and 4, respectively) was augmented by coadministration of budesonide. Similarly, PGE2-, and FSK-induced cAMP production in
HASM (Figure 5C and D) was augmented by budesonide co-administration. Despite the
cADDis characterizing budesonide’s effects on CTX-induced cAMP production, CTX
induced such saturating levels of cAMP production in HASM cells making us unable to
detect a synergism above CTX stimulation alone (data not shown).
Interestingly, synergism between glucocorticoids and β2 agoinsts has been
examined previously. A recent study noted that beclomethasone augmented formoterolinduced reversal of pre-contracted airways (26), to about ~30% maximally (27). Although
there was synergism between the two therapeutics, the beclomethasone dose was given
overnight, with effects likely genomic. This is in direct contrast to what our studies show,
where despite budesonide inducing cAMP production in HASM, it alone was unable to
induce bronchodilation even at a concentration of 100 µM. Additionally, the 2016 study
utilized non-selective inhibitors of PKA and Gαs to establish roles for those protein in
beclomethasone-induced bronchodilation in lung slices. Our studies have the advantage
of observing cAMP production in live primary HASM in real time, a system in which we
can genetically manipulate components of signaling pathways to more rigorously
ascertain the necessity and sufficiency specific molecules in the responses we observe.
Our studies identify mechanisms by which budesonide, a potent glucocorticoid,
rapidly activates cAMP production and augments agonist-mediated bronchodilation. This
is the first direct demonstration that glucocorticoids stimulate cAMP production in airway
smooth muscle. These mechanisms may explain, in part, how combination therapy of β2

agonists and ICS offer greater efficacy in comparison to either drug alone. Interestingly,
these beneficial effects occur separate and distinct from any anti-inflammatory effects
(11). Combination therapy represents a cornerstone for maintenance therapy in asthma
and COPD. Evidence also suggests that this combination can serve as an antiinflammatory reliever therapy (when added to maintenance) that decreases exacerbation
rates, improves asthma symptoms, and enhances lung function as compared to higher
doses of inhaled corticosteroids (ICS) alone (4-6). Our data identify molecular
mechanisms by which steroids and long-acting β2 agonists together improve
bronchodilation.
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Figure

1

–

Acute

budesonide

stimulation

augments

formoterol-induced

bronchodilation, but does not induce bronchodilation alone. (A) Simultaneous
stimulation of hPCLS with budesonide (10-5 M) with formoterol (10-12 – 10-6 M) augments
(B) maximal bronchodilation (formoterol vs. budesonide at 10-6 M formoterol, 71.4 ± 5%
vs. 89.7 ± 7.3%), and increases the integrated (C) area under the curve vs. formoterol
alone (formoterol vs. formoterol + budesonide, 156.8 ± 25.9 vs. 257.1 ± 51.6). Data
represents n=15-25 donors, p<0.05 vs formoterol alone. (D) Budesonide alone does not
induce bronchodilation in hPCLS. Data represents 2 (budesonide alone) - 15 (formoterol)
donors, 6-36 slices/condition.

(A)

(B)

(C)

Figure 2 – Simultaneous budesonide treatment augments PGE2-induced
bronchodilation of human small airways. Budesonide (10 µM) was given
simultaneously with PGE2 (10-10 – 10-5 M) and bronchodilation was assessed.
Concentration-response curves (A) are represented as % dilation for the combination
compared to PGE2-induced dilation alone. Maximal bronchodilation at 10-5 M PGE2 (B,
PGE2 vs. PGE2 + budesonide at a maximum of 10-5 M PGE2, 116.6 ± 16.6% vs. 283.3 ±
37.3%) and integrated area under the curve (C, PGE2 vs. PGE2 + budesonide, 264.5 ±
40 vs. 736.2 ± 209.6) of PGE2-induced bronchodilation were significantly increased. Data
represents n=3 donors, *p<0.05 compared to PGE2 stimulation alone.

(A)

(B)

Figure

(C)

3

–

Budesonide

significantly

augments

cholera

toxin-induced

bronchodilation of human small airways. Budesonide (10 µM) was given
simultaneously with cholera toxin (CTX, 0.01-100 µg/ml) and bronchodilation was
assessed. Concentration-response curves (A) were normalized to CTX stimulation alone
set to 100%. Maximum bronchodilation at 100 µg/mL (B, CTX vs. CTX + budesonide at a
maximum of 100 µg/ml CTX, 105.5 ± 3.9% vs. 128.4 ± 17.5%) and area under the curve
(C, (CTX vs. CTX + budesonide, 200.8 ± 13.8 vs. 361.5 ± 112.6) were significantly
increased with budesonide stimulation. Data are representative of n=5 donors, 11-13
slices/condition, *p<0.05 compared to CTX stimulation alone.

(A)

(B)

(C)

Figure 4 – Budesonide augments forskolin-induced bronchodilation of human
small airways. Budesonide (10 µM) was given simultaneously with forskolin (Fsk, 10-12
– 10-5 M) and bronchodilation was assessed. Concentration-response curves to Fsk (A)
were plotted. Maximal bronchodilation at 10-5 M FSK (B, FSK vs. FSK + budesonide at
maximum of 10-5 M FSK, 83.7 ± 8.5% vs. 110.1 ± 10.6%) and area under the curve (C,
FSK vs. FSK + budesonide, 151.9 ± 11.8 vs. 232.3 ± 29.1) were significantly increased
in the presence of budesonide. Data are representative of n=5 donors, * p<0.05 compared
to control/Fsk.
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(B)

(C)

(D)

(E)

Figure 5 – Budesonide alone induces cAMP production in HASM cells, and
enhances formoterol, PGE2, and forskolin-induced cAMP production. HASM cells
were incubated with recombinant BacMam virus expressing the cADDis cAMP sensor for
24 hr. After establishing baseline, fluorescence decay was monitored for 30 min after
addition of drug. (A) cADDis sensor fluorescent decay curves elicited by various
concentrations of formoterol were fit by one-phase decay non-linear regression analysis
(inset, 10-12 – 10-6 M formoterol, log EC50 of -7.78 ± 0.185). The rate (K) was multiplied
by the steady state change in fluorescence (plateau) for each concentration of formoterol.

Each point represents the mean ± SEM of n=5. (B) Budesonide alone (1 or 10 µM) elicits
cAMP production in cells, and is compared to forskolin (10 µM) stimulation. Each point
represents the mean ± SEM of n=4-6 cell lines and lines represent the fit by one-phase
decay non-linear regression analysis. * denotes p < 0.05, ** denotes p < 0.01 of each time
point compared to vehicle using multiple t tests and the Holm-Sidak method for correction
of multiple comparisons. (C) Formoterol concentration-responses curves in the presence
of vehicle or 1 µM budesonide. Each point represents the mean ± SEM of n=5 cell lines
(log EC50 formoterol vs. formoterol + budesonide, -7.76 ± 0.205 vs. -8.36 ± 0.189,
p=0.021). (D) PGE2 concentration-responses curves in the presence of vehicle or 1 µM
budesonide. Each point represents the mean ± SEM of n=4 cell lines (log EC50 PGE2 vs.
PGE2 + budesonide, -7.85 ± 0.062 vs. -8.78 ± 0.129, p=0.046). (E) Forskolin
concentration-responses curves in the presence of vehicle or 1 µM budesonide. Each
point represents the mean ± SEM of n=7 cell lines (log EC50 FSK vs. FSK + budesonide,
-6.75 ± 0.168 vs. -7.67 ± 0.190, p=0.005).

(A)

(B)

Figure 6 - mGR exists in HASM. (A) HASM from non-diseased lung donors was
biotinylated and purification of a membrane fraction determined the existence of a
membrane bound form of the glucocorticoid receptor. Presence of the epidermal growth
factor receptor (EGFR) and absence of GAPDH and COX IV (cytosolic proteins) were
used as controls for purity of membrane protein isolation. (B) HASM cells were fixed with
acetone following stimulation for 30 min with dexamethasone (1 µM). Fixed cells were
then probed for glucocorticoid receptor and DAPI. Data are representative of 3 separate
non-asthma donors for both (A) and (B).

(A)

(B)

Figure 7 – Budesonide augments formoterol-mediated attenuation of carbachol
(Cch)-induced phosphorylation of myosin light chain. HASM cells were treated with
Cch (25 µM, 15 min), then treated simultaneously with formoterol (10 pM – 10 nM, 5 min)
and budesonide (1 µM, 5 min). Phosphorylation of myosin light chain was assessed by
immunoblot, using total myosin light chain as a loading control (A). Data are expressed
as fold compared to control (B), and are representative of 5 separate HASM donors (*
p<0.05).

Figure 8 – Knockdown of GRα had little effect on budesonide or budesonide +
formoterol-induced cAMP production in HASM. HASM were transfected with siRNA
specific for GRαor scrambled control (mock) for 72 hr. A: Lysates were collected and
analyzed by immunoblotting using antibodies specific for GRα or β-actin. Each lane
shows one of 3 separate experiments on individual cell lines. B, C and D: cADDis sensor
was expressed in HASM with a recombinant BacMam virus then cAMP responses to

budesonide (1 µM, B), formoterol (0.1 nM, C) or both budesonide and formoterol (1 µM
and 0.1 nM, respectively, D) were measured in HASM were transfected with nontargeting siRNA or siRNA specific for GRα. Each point represents the mean ± SEM of
n=4-5 cell lines.
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